Dr. Johan Luthman has been appointed Executive Vice President and Head of Research & Development in Lundbeck.
Luthman will assume his new role and join the Executive Management on 1 March 2019 and brings approximately 28 years of experience in pharmaceutical R&D. He has been exposed to R&D management from companies such as Eisai, Merck & Co and AstraZeneca and has taken through development of small molecules and biopharmaceuticals (mAb and protein therapeutics) programs in neuroscience (neurology, psychiatry, pain and ophthalmology), metabolic diseases and immunology & inflammation areas.
“I look forward to welcoming Johan to his new position in Lundbeck,” says Deborah Dunsire; President and CEO of Lundbeck. “This is a critical role here as scientific innovation and development are at the center of our mission to enable people living with brain disease to be their best. Johan’s extensive experience will be vital to enabling Lundbeck drive the innovation choices we need to make to bring transformative medicines to patients and remain a sustainable growth company in the coming years”.
A PhD in neurobiology and Histology
Johan Luthman is living in the U.S. and grew up in Sweden where he graduated in Dental Sciences from Karolinska Institute in 1984. Johan also holds a PhD in Neurobiology and Histology. In connection with his new position, Johan plans to move to Denmark from the U.S.
“I am delighted to have been given the opportunity to join Lundbeck and head the company’s research and development organization,” says Dr. Johan Luthman. “From almost three decades in the industry I know Lundbeck as a strong scientific company with a great history of bringing forward new and innovative treatments. I am excited to be part of Lundbeck and help build on its strong heritage.”